
UnicoCell — Investor Relations & Filings
UnicoCell Biomed Co., Ltd. specializes in regenerative medicine, focusing on the research, development, and clinical application of stem cell technologies. The company’s operations are centered on three primary axes: the development of novel stem cell therapeutics, the production of stem cell-derived exosomes, and the provision of cell manufacturing and Contract Development and Manufacturing Organization (CDMO) services. Its lead candidate, ELIXCYTE, is an adipose-derived stem cell therapy undergoing Phase 3 clinical trials for indications such as knee osteoarthritis and chronic kidney disease. Additionally, the company maintains an allogeneic stem cell bank and provides autologous adipose-derived stem cell therapy services. Utilizing patented manufacturing processes and proprietary technology, UnicoCell offers integrated solutions from research to large-scale production to address unmet medical needs in the regenerative therapy sector.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 本公司脂肪幹細胞新藥ELIXCYTE治療膝骨關節炎 (Knee Osteoarthritis)之人體臨床試驗,向衛生福利部 提出申請臨床試驗設計變更。 | 2026-05-29 | Chinese | |
| 功能性委員會成員 | 2026-05-21 | Chinese | |
| 功能性委員會成員 | 2026-05-21 | Chinese | |
| 公告本公司董事會委任薪資報酬委員會委員 | 2026-05-20 | Chinese | |
| 公告本公司審計委員會委員異動 | 2026-05-20 | Chinese | |
| 公告本公司董事會選任董事長 | 2026-05-20 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47889775 | 本公司脂肪幹細胞新藥ELIXCYTE治療膝骨關節炎 (Knee Osteoarthritis)之人體臨床試驗,向衛生福利部 提出申請臨床試驗設計變更。 | 2026-05-29 | Chinese | ||
| 46707409 | 功能性委員會成員 | 2026-05-21 | Chinese | ||
| 46707411 | 功能性委員會成員 | 2026-05-21 | Chinese | ||
| 46586514 | 公告本公司董事會委任薪資報酬委員會委員 | 2026-05-20 | Chinese | ||
| 46586515 | 公告本公司審計委員會委員異動 | 2026-05-20 | Chinese | ||
| 46586516 | 公告本公司董事會選任董事長 | 2026-05-20 | Chinese | ||
| 46586518 | 公告本公司115年股東常會通過解除董事競業禁止之限制 | 2026-05-20 | Chinese | ||
| 46584900 | 公告本公司115年股東常會重要決議事項 | 2026-05-20 | Chinese | ||
| 46584942 | 公告本公司115年股東常會董事改選當選名單(含獨立董事) | 2026-05-20 | Chinese | ||
| 46577281 | 公司治理組織架構 | 2026-05-20 | Chinese | ||
| 45809303 | 115年第1季財務報告書 — 202601_6794_AI2.pdf | 2026-05-12 | Chinese | ||
| 45746236 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45741522 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741333 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45740917 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
RenovoRx, Inc.
A clinical-stage company developing targeted oncology thera…
|
RNXT | US | Professional, scientific and te… |
|
Repare Therapeutics Inc.
A clinical-stage oncology company developing targeted cance…
|
RPTX | US | Professional, scientific and te… |
|
Replimune Group, Inc.
A clinical-stage biotech developing oncolytic immunotherapi…
|
REPL | US | Professional, scientific and te… |
|
ReproCELL Incorporated
Provider of stem cell technology and services for research …
|
4978 | JP | Professional, scientific and te… |
|
RESEARCH FRONTIERS INC
Develops and licenses patented light-control technology for…
|
REFR | US | Professional, scientific and te… |
|
RESONANCE HEALTH LIMITED
Develops non-invasive MRI software for quantitative analysi…
|
RHT | AU | Professional, scientific and te… |
|
Respiratorius AB
A research company developing innovative drug candidates, p…
|
RESP | SE | Professional, scientific and te… |
|
REVELATION BIOSCIENCES, INC.
Clinical-stage biopharma developing immunologic therapies t…
|
REVB | US | Professional, scientific and te… |
|
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Clinical-stage biopharma developing therapeutics for CNS, r…
|
RVPH | US | Professional, scientific and te… |
|
Revolution Medicines, Inc.
Clinical-stage precision oncology company developing therap…
|
RVMD | US | Professional, scientific and te… |
UnicoCell via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52633/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52633 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52633 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52633 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52633}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for UnicoCell (id: 52633)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.